Dalbeth N - Search Results

1

Effects of Allopurinol on the Progression of Chronic Kidney Disease.

Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, Clarke P, Dalbeth N, Day RO, de Zoysa JR, Douglas B, Faull R, Harris DC, Hawley CM, Jones GRD, Kanellis J, Palmer SC, Perkovic V, Rangan GK, Reidlinger D, Robison L, Walker RJ, Walters G, Johnson DW; CKD-FIX Study Investigators. Badve SV, et al. Among authors: dalbeth n. N Engl J Med. 2020 Jun 25;382(26):2504-2513. doi: 10.1056/NEJMoa1915833. N Engl J Med. 2020. PMID: 32579811 Clinical Trial.

2

Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.

Dalbeth N, Kumar S, Stamp L, Gow P. Dalbeth N, et al. J Rheumatol. 2006 Aug;33(8):1646-50. J Rheumatol. 2006. PMID: 16783857

3

Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.

Dalbeth N, Stamp L. Dalbeth N, et al. Semin Dial. 2007 Sep-Oct;20(5):391-5. doi: 10.1111/j.1525-139X.2007.00270.x. Semin Dial. 2007. PMID: 17897242

4

Debunking the myths to provide 21st Century management of gout.

Winnard D, Kake T, Gow P, Barratt-Boyes C, Harris V, Hall DA, Mason H, Merriman T, Dalbeth N; Maaori Gout Action Group in Counties Manukau District Health Board. Winnard D, et al. Among authors: dalbeth n. N Z Med J. 2008 May 23;121(1274):79-85. N Z Med J. 2008. PMID: 18535649

5

Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.

Dalbeth N, Merriman T. Dalbeth N, et al. Rheumatology (Oxford). 2009 Mar;48(3):222-6. doi: 10.1093/rheumatology/ken460. Epub 2008 Dec 24. Rheumatology (Oxford). 2009. PMID: 19109320 Review.

6

The genetic basis of hyperuricaemia and gout.

Merriman TR, Dalbeth N. Merriman TR, et al. Among authors: dalbeth n. Joint Bone Spine. 2011 Jan;78(1):35-40. doi: 10.1016/j.jbspin.2010.02.027. Epub 2010 May 15. Joint Bone Spine. 2011. PMID: 20472486 Review.

7

The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity.

Hollis-Moffatt JE, Gow PJ, Harrison AA, Highton J, Jones PB, Stamp LK, Dalbeth N, Merriman TR. Hollis-Moffatt JE, et al. Among authors: dalbeth n. Arthritis Res Ther. 2011 Jun 9;13(3):R85. doi: 10.1186/ar3356. Arthritis Res Ther. 2011. PMID: 21658257 Free PMC article.

8

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N. Stamp LK, et al. Among authors: dalbeth n. Arthritis Rheum. 2012 Aug;64(8):2529-36. doi: 10.1002/art.34488. Arthritis Rheum. 2012. PMID: 22488501 Free article.

9

Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load.

Dalbeth N, House ME, Gamble GD, Horne A, Pool B, Purvis L, Stewart A, Merriman M, Cadzow M, Phipps-Green A, Merriman TR. Dalbeth N, et al. Ann Rheum Dis. 2013 Nov;72(11):1868-73. doi: 10.1136/annrheumdis-2012-202732. Epub 2013 Jan 24. Ann Rheum Dis. 2013. PMID: 23349133

10

Population-specific effects of SLC17A1 genotype on serum urate concentrations and renal excretion of uric acid during a fructose load.

Dalbeth N, House ME, Gamble GD, Horne A, Purvis L, Stewart A, Merriman M, Cadzow M, Phipps-Green A, Merriman TR. Dalbeth N, et al. Ann Rheum Dis. 2014 Jan;73(1):313-4. doi: 10.1136/annrheumdis-2013-203767. Epub 2013 Jul 12. Ann Rheum Dis. 2014. PMID: 23852697 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

603 results

Search Page